Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Iman Abou Dalle; Remy Dulery; Nour Moukalled; Laure Ricard; Nicolas Stocker; Jean El-Cheikh; Mohamad Mohty; Ali Bazarbachi

doi:10.1038/s41408-024-00989-w

Blood Cancer Journal (Jan 2024)

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Iman Abou Dalle,
Remy Dulery,
Nour Moukalled,
Laure Ricard,
Nicolas Stocker,
Jean El-Cheikh,
Mohamad Mohty,
Ali Bazarbachi

Affiliations

Iman Abou Dalle: Hematology-Oncology Division, American University of Beirut Medical Center
Remy Dulery: Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938
Nour Moukalled: Hematology-Oncology Division, American University of Beirut Medical Center
Laure Ricard: Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938
Nicolas Stocker: Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938
Jean El-Cheikh: Hematology-Oncology Division, American University of Beirut Medical Center
Mohamad Mohty: Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938
Ali Bazarbachi: Hematology-Oncology Division, American University of Beirut Medical Center

DOI: https://doi.org/10.1038/s41408-024-00989-w
Journal volume & issue: Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin’s lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.

Published in Blood Cancer Journal

ISSN: 2044-5385 (Online)
Publisher: Nature Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.nature.com/bcj/index.html

About the journal